# Hypothalamic and Pituitary Agents
<!-- toc -->
## Gonadotropins Releasing Hormone (GnRH)
**Leuprolide & Goserelin & Histrelin & Nafarelin**
*MOA:*
* GnRH Agonist
  * Acting on Anterior Pituitary
* GPCR->G4 ->IP3 & Ca2+

**Physiology Principle**
* GnRH Pulsatile -> Increase FSH/LH
  * Physiologic
* Continuous GnRH -> Decreases FSH/LH (Negative feedback)

*Uses:*

* Precocious puberty, Endometriosis, Polycystic
ovarian syndrome, Uterine Fibroids, Gonadal Steroid Prostate Cancer
* Suppression of LH during infertility treatment
* Suppression of Puberty in Transgender individuals

*SE:*
* **Initial Flair** (prevent with antiandrogens)
* Symptoms of hypogonadism, detrimental effects on bone mineralization and lipids

## Gonadotropins Releasing Hormone Antagonists (GnRH)
**Ganirelix acetate & Cetrorelix acetate & Degarelix acetate**

*MOA:*
* **Antagonist of GnRH Receptor**
  * Decrease of LH secretion > FSH
* Developed to avoid the flare phenomenon observed with GnRH agonists.

*Use:*
* **Infertility**-> Inhibit premature LH surges for women undergoing controlled ovarian stimulation.
* **Degarelix** -> Advanced prostate cancer

## Vasopressin or Antidiuretic Hormone (ADH)
**Arginine Vasopressin (AVP)**

*MOA:*
* GPCR
  * V1->Gq->IP3 & Ca2+
  * V2->Gs->cAMP
* V1 - Contraction of Gl and Vascular Smooth muscle
* V2 - insertion of Aquaporin into Renal collecting ducts

*Uses:* **Shock / Hypotension (V1)**

*SE:*
* V1 effects
  * **Vasoconstriction (esp. Coronary vessels)**
  * **Stimulation of GI muscles**
* Cross-react with oxytocin receptor -> Stimulation of uterine muscle

**Desmopressin**

*MOA:*
* Longer duration of action
* Renal selectivity

*Uses:*
* **Central Diabetes Insipidus**
  * Replace absent ADH
* **Differentiate between Central and Nephrogenic DI**
* Nocturnal enuresis
* **VWF Disease**
  * Stimulates release vWF from endothelial cells

### Syndrome of Inappropriate ADH Secretion (SIADH)

**Inability to excrete free water -> hyponatremia & hypo-osmolality**

*Causes:*
1. Ectopic malignant **neoplasms**
2. CNS Trauma and infection
3. Endocrine disease
4. **Drug** (Cyclophosphamide, SSRIs, Carbamazepine, elc.)

*Treatment:*
* Water restriction
* **Tolvaptan** (V2 antagonist)
* **Demeclocycline**
  * Reduces renal sensitivity to AVP
  * Nephrotoxic: monitor renal function

## Somatotropin (Human growth hormone)
**Somatropin (rhGH) - Recombunant Human Growth hormone**

*MOA:*
* **Mitogenic and antiapoptotic effects**
* **Metabolic effects:** triglyceride hydrolysis. protein synthesis, and insulin resistant
* **Actions:** increase collagen, skeletal growth, soft tissus growth

*Admin:* SubQ befors badtime (mimicking normal sacraton pattern)

*Uses in Kids:*
* **GH deficiency**
* Very short stature children without GH deficiency
* Conditons of impaired growth

*Uses in Adults:*
* GH Deficlency
* HIV-related wasting of cachexia

*SE:*
* Children: Few
* Adults: **peripheral edema, myalgias, arthalgia. carpal tunnel syndrome**

## Insulin like Growth Factor-1
**Mecasermin (rhiGF-1) - Recombinant Insulin like Growth Factor-1**

*MOA:* IGF-1 Receptor -> Receplor Autophosphorylation (Insulin like).
**Mediates the effects of GH**

*Uses in Kids:*
* Long term treatment of growth fallure with severe IGF-1 deficiency.
* GH gene deletion with neutralizing Ab

*Admin:* SubQ 2 times a day. Before or after meal 1o prevent hypoglycemia

*Contraindication:*
* Not after closure of epiphyses
* Malignancy

*SE:* Hypoglycemia

## Pegvisomant - Recombinant hGH analog
*MOA:*
* Competitive inhibitor (Antagonist) of endogenous GH
  * Lysine 120 replaced by glycine -> prevents functional receptor dimerization.

Pegylated?
* Polyethylene glycol chains conjugated to primary structure.
* Increases half life!
* Reduces immunogenicity!

*Uses:* **Acromegaly (most effective)**

*SE:*
* Increased LFTs
  * Monitor liver function
* Contraindicated in Pre Existing increased LFTs

*Diabetics may require dose reductions*

## Somatostatin (SRIF) - Somatotropin releasing-inhibiting factor
*Somatostatin analogs* **Octreotide & Lanreotide & Pasireotide**

*MOA:*
* CPCR - > Gi -> Decrease cAMP
* **Decreases GH secretion, TSH, and Gl peptide hormones (Insulin, glucagon, VIP, and gastrin).**

**Octreotide**

*Efficacy:* potent inhibitor of GH secretion. Less potent at Inhibiting insulin secretion

*Uses:*
* **Acromegaly (excess GH secreton)**
* Carcinoid tumors
* **Portal hypertension & Gl Bleeds**

*SE:*
* Reduction of Bile production
* Gallbladder contractility, GI disturbances
* Pain, nausea, and diarrhea

**Pasireotide**

*MOA:*
* Tumor cells over-express **somatostatin receptor 5 (SSTRS5)**
* Selectively binds SSTR5 and inhibit ACTH secretion, decreasing Cortisol section

*Uses:* Treatment of **Cushing's disease** (Surgery ineffective or not curative)

*SE:*
* Diarrhea, nausea
* Hyperglycemia
* Cholelithiasis, abdominal pain
* Headache, fatigue

## Dopamine Agonists
**Bromocriptine & Cabergoline**

*MOA:*
* D2 agonist
* **Cabergoline > Bromocriptine effectiveness**
* Ergot alkaloid derivatives
* Nonspecific

*Uses:*
* Acromegaly & Prolactin hypersecretion (Last Line)
  * Pituitary Adenomas have D2 receplors that respond by decreasing section when activated

Usually combined with Octreotide

*SE:*
* Nausea, vomiting, dizziness
* hypotension
* abdominal cramps
* arrhythmias
* sleep disturbances

## Uterine Stimulants
**Oxytocin**

*MOA:*
* GPCR-> Gq ->IP3 & Ca2+
* Increase **frequency and force of uterine contraction**
* **Milk ejection**

Uses:
* **Induction of labor**
* **Control of postpartum bleeding**

Side Effects:
* **Uterine rupture**
* **Trauma or death to the infant**

**Methylergonovine (Methergine)**

*MOA:* Ergot alkaloid (5-HT2A)

*Use:* **Vasoconstrictor used to control postpartum uterine bleeding**

*SE:* **Contraindicated in Hypertension**

**Dinoprostone (Cervidil)**

*MOA:* Prostaglandin - PGE2

*Use:* **Cervical Ripening**

**Carboprost (Hemabate)**

*MOA:* **Prostaglandin - 15-methyl PGF2a**

*Use:* **Control postpartum bleeding**

## Gonadotropins
*LH activity:*
**Human chorionic gonadotropin (hCG) & Recombinant human chorionic gonadotropin**

*Equivalent LH and FSH activity:*
**Human menopausal gonadotropin (hMG; menotropin)**

*FSH activity:*
**Recombinant human FSH (rFSH) & Urofollitropin (uFSH)**

*MOA:* GPCR -> Gs -> cAMP

**Females**

**FSH** -> Development of Ovarian Follicles

**LH** -> Production of Estrogen and Progesterone & Induces ovulation

**Males**

**FSH** -> Produces androgen-binding globulin. Maintains sufficient
testosterone levels in seminiferous tubules for spermatogenesis.

**LH** -> Produces Testosterone

**Uses in males & females:**
1. Ovarian Stimulation
*  Follicle growth (FSH) & Ovulation (LH)
*  Side Effects: Multiple births & Ovarian hyperstimulation syndrome (OHSS)
2. Male hypogonadism and infertility
*  Testosterone synthesis (LH) & Spermatogenesis (FSH & LH)
3. Cryptorchidism (Undescended Testis)
*  Diagnostic
  * No testosterone response (primary failure)
  * Normal testosterone (Secondary or tertiary failure)
